FIFTEEN-YEAR RADIOTHERAPY OUTCOMES OF THE RANDOMIZED PORTEC-1 TRIAL FOR ENDOMETRIAL CARCINOMA

Autor: Creutzberg, C.L., Nout, R.A., Lybeert, M.L.M., Warlam-Rodenhuis, C.C., Jobsen, J.J., Mens, J.W.M., Lutgens, L.C.H.W., Pras, E., Poll-Franse, L.V. van de, Putten, W.L.J. van, PORTEC Study Grp
Přispěvatelé: Medical and Clinical Psychology, Radiotherapie, RS: GROW - School for Oncology and Reproduction
Jazyk: angličtina
Rok vydání: 2011
Předmět:
Oncology
Cancer Research
INTERMEDIATE-RISK
medicine.medical_treatment
ComputingMilieux_LEGALASPECTSOFCOMPUTING
GYNECOLOGIC-ONCOLOGY-GROUP
law.invention
ADJUVANT CHEMOTHERAPY
POSTOPERATIVE RADIOTHERAPY
Quality of life
Randomized controlled trial
QUALITY-OF-LIFE
law
Stage (cooking)
Aged
80 and over
Radiation
Neoplasms
Second Primary
PHASE-III TRIAL
Middle Aged
Prognosis
LYMPHVASCULAR SPACE INVOLVEMENT
Radiation therapy
Treatment Outcome
Radiology Nuclear Medicine and imaging
Female
Randomized trial
PELVIC RADIATION-THERAPY
Adult
Risk
medicine.medical_specialty
Vaginal Neoplasms
Breast Neoplasms
Endometrial carcinoma
Prognostic factors
Disease-Free Survival
Stage ib
Internal medicine
Carcinoma
medicine
Humans
Radiology
Nuclear Medicine and imaging
External beam radiotherapy
Aged
Analysis of Variance
Intention-to-treat analysis
business.industry
medicine.disease
Long-term outcome
Endometrial Neoplasms
Surgery
CANCER MRC ASTEC
EXTERNAL-BEAM RADIOTHERAPY
Neoplasm Grading
Neoplasm Recurrence
Local
business
Zdroj: International Journal of Radiation Oncology-Biology-Physics, 81(4), E631-E638
International Journal of Radiation Oncology-Biology-Physics, 81(4), e631-8
International Journal of Radiation Oncology Biology Physics, 81(4), e631-e638. Elsevier Inc.
International Journal of Radiation Oncology Biology Physics, 81(4), E631-E638. ELSEVIER SCIENCE INC
International Journal of Radiation Oncology Biology Physics, 81(4), E631-E638. Elsevier Science
ISSN: 1879-355X
0360-3016
DOI: 10.1016/j.ijrobp.2011.04.013
Popis: Purpose: To evaluate the very long-term results of the randomized Post Operative Radiation Therapy in Endometrial Carcinoma (PORTEC)-1 trial for patients with Stage I endometrial carcinoma (EC), focusing on the role of prognostic factors for treatment selection and the long-term risk of second cancers.Patients and Methods: The PORTEC trial (1990-1997) included 714 patients with Stage IC Grade 1-2 or Stage IB Grade 2-3 EC. After surgery, patients were randomly allocated to external-beam pelvic radiotherapy (EBRT) or no additional treatment (NAT). Analysis was by intention to treat.Results: 426 patients were alive at the date of analysis. The median follow-up time was 13.3 years. The 15-year actuarial locoregional recurrence (LRR) rates were 6% for EBRT vs. 15.5% for NAT (p 60 (HR 3.9, p = 0.002 for LRR and 2.7, p = 0.01 for EC death) and myometrial invasion > 50% (HR 1.9, p = 0.03 and HR 1.9, p = 0.02).Conclusions: The 15-year outcomes of PORTEC-1 confirm the relevance of HIR criteria for treatment selection, and a trend for long-term risk of second cancers. EBRT should be avoided in patients with low-and intermediate-risk EC. (C) 2011 Elsevier Inc.
Databáze: OpenAIRE
Externí odkaz: